Drugs for Zika Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 20)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Hydroxychloroquine |
Approved |
Phase 3 |
|
118-42-3 |
3652 |
Synonyms:
(+-)-Hydroxychloroquine
(±)-hydroxychloroquine
118-42-3
2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-chloro-4-Quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol
2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
5-22-10-00280 (Beilstein Handbook Reference)
747-36-4 (sulfate (1:1) salt)
7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(Ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline
7-chloro-4-[4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
7-chloro-4-[5-(N-Ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
AC1L1GEW
Axemal
BRN 0253894
C07043
C18H26ClN3O
CHEMBL1535
CID3652
D08050
DB01611
DivK1c_000942
Dolquine
EINECS 204-249-8
Ercoquin
Gen-Hydroxychloroquine 200mg Tablets
HCQ
|
Hidroxicloroquina
Hidroxicloroquina [inn-spanish]
Hidroxicloroquina [INN-Spanish]
HMS502P04
Hydroxychlorochin
Hydroxychloroguine
hydroxychloroquine
Hydroxychloroquine
Hydroxychloroquine (INN)
Hydroxychloroquine [INN:BAN]
Hydroxychloroquine sulfate
Hydroxychloroquine sulfate (1:1) salt
Hydroxychloroquine Sulfate (1:1) Salt
Hydroxychloroquinum
Hydroxychloroquinum [inn-latin]
Hydroxychloroquinum [INN-Latin]
IDI1_000942
Idrossiclorochina
Idrossiclorochina [dcit]
Idrossiclorochina [DCIT]
KBio1_000942
LS-66614
MolPort-003-847-792
NCGC00159483-02
NINDS_000942
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
PlaqueN/A
Plaquenil
Polirreumin
Polirreumin (TN)
Quensyl
SPBio_001116
Spectrum2_001238
Spectrum5_001697
ST072188
UNII-4QWG6N8QKH
WIN 1258
|
|
2 |
|
Ivermectin |
Approved, Investigational, Vet_approved |
Phase 3 |
|
70288-86-7 |
6474909 |
Synonyms:
(2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-[(1S)-1-methylpropyl]-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside
71827-03-7
AB00513813
AC1MJ4GR
AC1N7O27
BPBio1_000322
BRD-K24652731-001-02-7
BSPBio_000292
CHEMBL341047
CID11957587
CID4330618
CID6321424
CID6419971
CID6427057
EU-0100693
FT-0082656
HMS1568O14
HMS2089M09
I 8898
I8898_SIGMA
|
Ivermectin
IVERMECTIN
Ivermectina
Ivermectine
Ivermectinum
Lopac0_000693
MK-933
MLS001333247
MLS001333248
MLS002153248
MolPort-006-394-715
NCGC00094047-01
NCGC00094047-02
NCGC00094047-03
Prestwick_516
Prestwick2_000156
Prestwick3_000156
S1351_Selleck
SMR000857211
|
|
3 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
4 |
|
Antiparasitic Agents |
|
Phase 3 |
|
|
|
5 |
|
Antiprotozoal Agents |
|
Phase 3 |
|
|
|
6 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
7 |
|
Antimalarials |
|
Phase 3 |
|
|
|
8 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
9 |
|
Aluminum sulfate |
Approved |
Phase 1 |
|
10043-01-3 |
|
Synonyms:
Aluminium sulfate
Aluminium sulfate anhydrous
Aluminum sulfate anhydrous
|
Aluminum sulphate anhydrous
Dialuminum sulfate
Dialuminum trisulfate
|
|
10 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 1 |
|
21645-51-2 |
|
Synonyms:
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
|
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
|
|
11 |
|
Immunoglobulins, Intravenous |
|
Phase 1 |
|
|
|
12 |
|
Rho(D) Immune Globulin |
|
Phase 1 |
|
|
|
13 |
|
gamma-Globulins |
|
Phase 1 |
|
|
|
14 |
|
Immunoglobulin G |
|
Phase 1 |
|
|
|
15 |
|
Antibodies, Blocking |
|
Phase 1 |
|
|
|
16 |
|
Antibodies |
|
Phase 1 |
|
|
|
17 |
|
Immunoglobulins |
|
Phase 1 |
|
|
|
18 |
|
Antibodies, Monoclonal |
|
Phase 1 |
|
|
|
19 |
|
Vaccines |
|
Phase 1 |
|
|
|
20 |
|
Pharmaceutical Solutions |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 67)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study |
Recruiting |
NCT03037164 |
Phase 3 |
|
2 |
Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial |
Recruiting |
NCT04391127 |
Phase 3 |
Hydroxychloroquine;Ivermectin;Placebo |
3 |
VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents |
Completed |
NCT03110770 |
Phase 2 |
|
4 |
A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region |
Completed |
NCT03014089 |
Phase 1 |
|
5 |
A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults |
Completed |
NCT02937233 |
Phase 1 |
|
6 |
VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, in Healthy Adults |
Completed |
NCT02996461 |
Phase 1 |
|
7 |
Safety and Pharmacokinetic Evaluation of Zika Virus Immune Globulin in Healthy Volunteers |
Completed |
NCT03624946 |
Phase 1 |
|
8 |
A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years |
Completed |
NCT03425149 |
Phase 1 |
|
9 |
Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults |
Completed |
NCT02809443 |
Phase 1 |
|
10 |
Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers |
Completed |
NCT02996890 |
Phase 1 |
|
11 |
Phase I, Placebo-Controlled, Double-Blind Study To Evaluate The Safety, Tolerability, AND Immunogenicity Of GLS-5700, Administered ID Followed By Electroporation In Dengue Virus-Seropositive Adults |
Completed |
NCT02887482 |
Phase 1 |
|
12 |
Phase I Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults |
Completed |
NCT03611946 |
Phase 1 |
|
13 |
Phase 1 First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers |
Completed |
NCT03443830 |
Phase 1 |
Tyzivumab |
14 |
VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults |
Completed |
NCT02840487 |
Phase 1 |
|
15 |
Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects |
Completed |
NCT02952833 |
Phase 1 |
Saline |
16 |
A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects |
Completed |
NCT02963909 |
Phase 1 |
|
17 |
Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine |
Completed |
NCT03055000 |
Phase 1 |
|
18 |
Phase 1 First-in-Human, Time Lagged, Single Ascending Dose Study of TY014 in Healthy Adult Volunteers (Safety Arm - 1A) and Sequential Time Lagged, Parallel-Group, Randomised, Placebo-Controlled, Double-Blind, Single Ascending Dose Study of TY014 in YF-17D Vaccine Strain-Challenged Healthy Adult Volunteers (Efficacy Arm - 1B) |
Completed |
NCT03776786 |
Phase 1 |
|
19 |
Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP |
Recruiting |
NCT04033068 |
Phase 1 |
|
20 |
Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients |
Recruiting |
NCT03776695 |
Phase 1 |
|
21 |
A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers Given as a Standalone Vaccine or Co-administered With the Chikungunya Virus (CHIKV) Candidate Vaccine ChAdOx1 Chik |
Recruiting |
NCT04015648 |
Phase 1 |
|
22 |
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults |
Active, not recruiting |
NCT04064905 |
Phase 1 |
|
23 |
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years |
Active, not recruiting |
NCT03343626 |
Phase 1 |
Placebo |
24 |
Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Adult Subjects Who Reside in a Flavivirus Endemic Area |
Active, not recruiting |
NCT03008122 |
Phase 1 |
|
25 |
Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection. |
Unknown status |
NCT03161444 |
|
|
26 |
Persistence of Zika Virus in Semen After Acute Infection |
Unknown status |
NCT02733796 |
|
|
27 |
Études Observationnelles Des conséquences néonatales et pédiatriques de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016 |
Unknown status |
NCT02810210 |
|
|
28 |
Études Observationnelles Des conséquences de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016 |
Unknown status |
NCT02916732 |
|
|
29 |
Effect of a Posture Adapter Use on Body Alignment in Standing Position on Children Between 12 and 24 Months Old With Zyka Virys Congenital Syndrome |
Unknown status |
NCT03227601 |
|
|
30 |
Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF |
Unknown status |
NCT03255369 |
|
|
31 |
Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for an Efficacy Trial of a Zika Virus Whole Virion, Purified Inactivated Vaccine |
Completed |
NCT03158233 |
|
|
32 |
The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01) |
Completed |
NCT02831699 |
|
|
33 |
Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA |
Completed |
NCT03776903 |
|
|
34 |
Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection During the First or Second Trimester of Gestation. |
Completed |
NCT03679728 |
|
|
35 |
Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection |
Completed |
NCT02979938 |
|
|
36 |
Rash Accompanied by Three or More Dengue-like Symptoms During Pregnancy and Microcephaly: Case-control Study |
Completed |
NCT02741882 |
|
|
37 |
Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors |
Completed |
NCT02794181 |
|
|
38 |
Efficacy of Aquatic Physiotherapy in Stress Level and Muscle Tone of Children Between 3 and 24 Months With Microcephaly by Zika Virus Congenital Syndrome |
Completed |
NCT03330600 |
|
|
39 |
Pilot Study to Detect Zika Virus in Sperm |
Completed |
NCT02874456 |
|
|
40 |
Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia |
Completed |
NCT03206541 |
|
|
41 |
Randomized Trial to Assess Parental Response to Different Presentations of Vaccination Data for Schools and Child Care Centers |
Completed |
NCT02957344 |
|
|
42 |
TRMC-Bio "Molecular Profiling of Gut Microbiome, Microbiome Metabolome, Serum Chemistry, and Metabolism-Associated SNPs in Elite Athletes" |
Completed |
NCT02818413 |
|
|
43 |
Spatial Repellent Products for Control of Vector-borne Diseases - Dengue |
Completed |
NCT03553277 |
|
|
44 |
Pilot Study to Detect DENGUE Virus in Sperm. |
Completed |
NCT03612609 |
|
|
45 |
Risk Evaluation of Fetal Nervous System and Neurodevelopment Disorders in Infants of Women Exposed to Zika Virus Infection During Pregnancy |
Recruiting |
NCT02943304 |
|
|
46 |
Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.r |
Recruiting |
NCT01099852 |
|
|
47 |
Children (CH) Cohort for the Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy |
Recruiting |
NCT03393286 |
|
|
48 |
World Mosquito Program - Colombia (WMP-COLOMBIA): The Impact of City-wide Deployment of Wolbachia-infected Mosquitoes on Arboviral Disease Incidence in Medellin and Bello, Colombia |
Recruiting |
NCT03631719 |
|
|
49 |
The International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy |
Recruiting |
NCT04118738 |
|
|
50 |
Neuro-COVID-19: Neurological Complications of COVID-19 |
Recruiting |
NCT04418609 |
|
|
|